We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
Cap. Flow
-$193M
Cap. Flow %
-4.53%
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$52.4M
2
CI icon
Cigna
CI
+$48.2M
3
UTHR icon
United Therapeutics
UTHR
+$38.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$29.4M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$28.9M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$105M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$93.6M
3
THC icon
Tenet Healthcare
THC
+$81.8M
4
BSX icon
Boston Scientific
BSX
+$39.8M
5
CYTK icon
Cytokinetics
CYTK
+$35.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
1
Edgewise Therapeutics
EWTX
$4.64B
$252M 5.92%
15,518,492
– –
BSX icon
2
Boston Scientific
BSX
$67.9B
$237M 5.57%
2,429,300
-383,900
-14% -$39.8M
LLY icon
3
Eli Lilly
LLY
$1.05T
$230M 5.4%
301,200
-36,400
-11% -$27.1M
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
$184M 4.33%
2,718,735
– –
ELVN icon
5
Enliven Therapeutics
ELVN
$4.24B
$163M 3.83%
7,959,538
– –
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$31.7B
$138M 3.23%
301,600
-40,300
-12% -$16.4M
SYK icon
7
Stryker
SYK
$127B
$133M 3.12%
359,200
– –
EW icon
8
Edwards Lifesciences
EW
$52B
$131M 3.08%
1,684,000
-24,000
-1% -$1.88M
ISRG icon
9
Intuitive Surgical
ISRG
$132B
$128M 3.02%
287,200
-3,800
-1% -$1.82M
ARGX icon
10
argenx
ARGX
$64B
$127M 2.99%
172,300
-35,700
-17% -$23.5M
SION
11
Sionna Therapeutics
SION
$265M
$109M 2.56%
3,704,959
– –
UPB
12
Upstream Bio Inc
UPB
$366M
$107M 2.52%
5,693,589
– –
IRON icon
13
Disc Medicine
IRON
$3.07B
$93.5M 2.2%
1,415,020
– –
CAI
14
Caris Life Sciences
CAI
$7.24B
$91.8M 2.16%
3,034,858
– –
SPRY icon
15
ARS Pharmaceuticals
SPRY
$586M
$83.3M 1.96%
8,288,510
– –
RNAM
16
DELISTED
Avidity Biosciences
RNAM
$71.4M 1.68%
1,638,886
-174,000
-10% -$7.03M
MBX
17
MBX Biosciences
MBX
$3.03B
$70.1M 1.65%
4,002,887
– –
CGON icon
18
CG Oncology
CGON
$6.59B
$69.6M 1.63%
1,726,850
-151,000
-8% -$4.39M
NTRA icon
19
Natera
NTRA
$47B
$69.1M 1.62%
429,300
-164,134
-28% -$26M
AXSM icon
20
Axsome Therapeutics
AXSM
$10.4B
$64.6M 1.52%
531,800
+103,900
+24% +$11.7M
TERN
21
DELISTED
Terns Pharmaceuticals
TERN
$56.8M 1.33%
7,562,971
– –
AVBP icon
22
ArriVent BioPharma
AVBP
$1.49B
$55.9M 1.31%
3,027,328
– –
MLYS icon
23
Mineralys Therapeutics
MLYS
$2.26B
$55.7M 1.31%
1,469,494
+709,143
+93% +$15.3M
EXAS
24
DELISTED
Exact Sciences
EXAS
$54.4M 1.28%
994,616
+387,300
+64% +$19.4M
CMPX icon
25
Compass Therapeutics
CMPX
$432M
$53.3M 1.25%
15,219,994
– –
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2025 Portfolio in Review

As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.

  • OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
  • OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
  • OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
  • OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
  • OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
  • OrbiMed opened 24 new positions and closed 18 in Q3 2025.
  • OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.